At a glance
- Originator Merck & Co
- Developer Banyu
- Class Antihyperglycaemics
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 14 Sep 2004 Discontinued - Preclinical for Obesity in Japan (unspecified route)
- 14 Sep 2004 Discontinued - Preclinical for Type-2 diabetes mellitus in Japan (PO)
- 26 Feb 2001 No-Development-Reported for Obesity in Japan (Unknown route)